Genetic Signatures

Genetic Signatures Limited – Annual Report 2021 NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 30 JUNE 2021 41 Note 26: Parent Entity Financial Information (a) Summary financial information: 2021 $’000s 2020 $’000s Assets Current Assets Cash and cash equivalents 29,394 31,010 Trade and other receivables 7,990 10,885 Inventory 11,054 5,505 Government grant receivable - 2,554 Total Current Assets 48,438 49,954 Non-Current Assets Plant and equipment 4,994 2,622 Right of use assets 389 734 Total Non-Current Assets 5,383 3,356 Total Assets 53,821 53,310 Liabilities Current Liabilities Trade and other payables 3,202 2,361 Provisions 862 657 Leases 334 313 Total Current Liabilities 4,398 3,331 Non-Current Liabilities Leases 65 428 Provisions 18 20 Total Non-Current Liabilities 83 448 Total Liabilities 4,481 3,779 Net Assets 49,340 49,531 Equity Issued capital 84,164 84,013 Reserves 3,469 1,985 Accumulated losses (38,293) (36,467) Total Equity 49,340 49,531 Profit/(loss) for the year (1,826) (1,132) Other comprehensive income/(loss) - - Total comprehensive income/(loss) for the year (1,826) (1,132) (b) Summary financial information: The Parent entity did not have any contingent liabilities as at 30 June 2021 or 30 June 2020. (c) Significant accounting policies: The accounting policies of the parent entity are consistent with those of the consolidated entity, as disclosed in note 1, except for the following: • Investments in subsidiaries are accounted for at cost, less any impairment, in the parent entity. Financial Report